BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Futibatinib (Lytgobi) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Futibatinib (Lytgobi)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05727176-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Futibatinib (Lytgobi): Phase 2 readout est. (NCT05727176)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2\, Cholangiocarcinoma.\nStudy: S
 tudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR
 2 Fusion or Rearrangement\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/futibatinib-lytgobi#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0572717
 6
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506955-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Futibatinib (Lytgobi): Phase 2/3 readout est. (NCT06506955)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2/3.\nStudy: Futibatinib in Patie
 nts Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Com
 bination Therapy.\nEstimated primary completion: April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06506955
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767075-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Futibatinib (Lytgobi): Phase 2 readout est. (NCT03767075)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2.\nStudy: A Modular Multi-Basket
  Trial to Improve Personalized Medicine in Cancer Patients (Basket of Bask
 ets)\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03767075
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04999761-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Futibatinib (Lytgobi): Phase 1 readout est. (NCT04999761)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 1\, Biliary Tract Cancer.\nStudy:
  AB122 Platform Study\nEstimated primary completion: June 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04999761
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Futibatinib (Lytgobi): Phase 3 readout est. (NCT05615818)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 3.\nStudy: Personalized Medicine 
 for Advanced Biliary Cancer Patients\nEstimated primary completion: June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/futibatinib-lytg
 obi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05615818
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06263153-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Futibatinib (Lytgobi): Phase 2 readout est. (NCT06263153)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2.\nStudy: Futibatinib in Combina
 tion With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invas
 ive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
 \nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06263153
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Futibatinib (Lytgobi): Phase 2 readout est. (NCT02693535)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2.\nStudy: TAPUR: Testing the Use
  of Food and Drug Administration (FDA) Approved Drugs That Target a Specif
 ic Abnormality in a Tumor Gene in People With Advanced Stage Cancer\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06722183-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Futibatinib (Lytgobi): Phase 2 readout est. (NCT06722183)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2.\nStudy: Futibatinib in Combina
 tion With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor 
 Entities\nEstimated primary completion: March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06722183
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710885-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Futibatinib (Lytgobi): Phase 3 readout est. (NCT07710885)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 3\, Biliary Tract Cancer.\nStudy:
  Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer\nEst
 imated primary completion: 30 April 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07710885
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594548-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20300909
DTEND;VALUE=DATE:20300910
SUMMARY:Futibatinib (Lytgobi): Phase 1 readout est. (NCT07594548)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 1.\nStudy: Futibatinib With Pacli
 taxel and Ramucirumab for the Treatment of Locally Advanced or Unresectabl
 e Gastric\, Gastroesophageal Junction\, or Esophageal Adenocarcinoma\nEsti
 mated primary completion: 9 September 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07594548
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639528-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20301210
DTEND;VALUE=DATE:20301211
SUMMARY:Futibatinib (Lytgobi): Phase 2 readout est. (NCT07639528)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 2\, Cholangiocarcinoma.\nStudy: P
 reoperative Durvalumab\, Cisplatin\, Gemcitabine With or Without Futibatin
 ib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangio
 carcinoma\, OPTIC Trial\nEstimated primary completion: 10 December 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/futibatinib-lytgobi#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076395
 28
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Futibatinib (Lytgobi): Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 1/2.\nStudy: European Proof-of-Co
 ncept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed 
 or Refractory Tumors\nEstimated primary completion: February 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745296-2756@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20330702
DTEND;VALUE=DATE:20330703
SUMMARY:Futibatinib (Lytgobi): Phase 3 readout est. (NCT07745296)
DESCRIPTION:Futibatinib (Lytgobi)\, phase 3\, Biliary Tract Cancer.\nStudy:
  Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract
  Cancer\nEstimated primary completion: 2 July 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07745296
URL:https://assetmemo.bio/drug/futibatinib-lytgobi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
